OCUL - Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) | Benzinga

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts.

Presentations at Eyecelerator (associated @ ASCRS 2024):

• Session Title: "Presenting Company Showcases"
  Session Date/Time: Thursday, April 4^th at 1 PM EST
  Location: Omni Boston Hotel at the Seaport – Breakout 2
  Presenter: Pravin U. Dugel, MD, Executive Chairman, Ocular Therapeutix

Presentations at ASCRS at the Boston Convention and Exhibition Center (BCEC)

• Title: Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: Results from a Phase 2 Clinical Trial
  Session Title: Glaucoma (Procedures and Medications)
  Session Date/Time: Saturday, April 6^th at 10 AM EST
  Location: Meeting Level 2, Room 257B
  Presenter: Mark J. Gallardo, MD

• Title: Incidence of Safety Events Following Cataract Surgery with Intracanalicular ...

Full story available on Benzinga.com